Table 2.
Comparison of medical history between patients in polypharmacy and nonpolypharmacy group.
| Medical history | Polypharmacy group n = 166 (53.5%) |
Nonpolypharmacy group n = 144 (46.5%) |
Statistical significance |
|---|---|---|---|
| Morbidity | |||
| Arterial hypertension | |||
| Yes | 125 (75.3%) | 79 (54.9%) | p = 0.001 |
| No | 41 (24.7%) | 65 (45.1%) | (χ2 = 14.317) |
| Hyperlipidemia/dyslipidemia | |||
| Yes | 49 (29.5%) | 20 (13.9%) | p = 0.001 |
| No | 117 (70.5%) | 124 (86.1%) | (χ2 = 10.885) |
| Diabetes mellitus | |||
| Yes | 72 (43.4%) | 30 (20.8%) | p = 0.001 |
| No | 94 (56.6%) | 114 (79.2%) | (χ2 = 17.745) |
| Stroke | |||
| Yes | 21 (12.7%) | 5 (3.5%) | p = 0.004 |
| No | 145 (87.3%) | 139 (96.5%) | (χ2 = 8.454) |
| Heart failure | |||
| Yes | 31 (18.7%) | 4 (2.8%) | p = 0.001 |
| No | 135 (81.3%) | 140 (97.2%) | (χ2 = 19.456) |
| Atrial fibrillation | |||
| Yes | 54 (32.5%) | 13 (9.0%) | p = 0.001 |
| No | 112 (67.5%) | 131 (91.0%) | (χ2 = 25.140) |
| Coronary artery disease | |||
| Yes | 51 (30.7%) | 7 (4.9%) | p = 0.001 |
| No | 115 (69.3%) | 137 (95.1%) | (χ2 = 33.909) |
| Chronic renal failure | |||
| Yes | 9 (5.4%) | 1 (0.7%) | p = 0.023 |
| No | 157 (94.6%) | 143 (99.3%) | (χ2 = 5.520) |
| COPD | |||
| Yes | 23 (13.9%) | 7 (4.9%) | p = 0.011 |
| No | 143 (86.1%) | 137 (95.1%) | (χ2 = 7.137) |
| Dementia | |||
| Yes | 31 (18.7%) | 11 (7.6%) | p = 0.005 |
| No | 135 (81.3%) | 133 (92.4%) | (χ2 = 8.018) |
| Benign prostate hyperplasia | |||
| Yes | 14 (8.4%) | 4 (2.8%) | p = 0.049 |
| No | 152 (91.6%) | 140 (97.2%) | (χ2 = 4.510) |
| Thyroid diseases | |||
| Yes | 24 (14.5%) | 9 (6.3%) | p = 0.026 |
| No | 142 (85.5%) | 135 (93.8%) | (χ2 = 5.461) |
| Hyperuricemia | |||
| Yes | 19 (11.4%) | 4 (2.8%) | p = 0.004 |
| No | 147 (88.6%) | 140 (97.2%) | (χ2 = 8.435) |
|
| |||
| CCI (95% CI) | 5.77 (5.54–5.99) | 5.13 (4.79–5.50) |
p = 0.001 (U = 7798.000) |
COPD: chronic obstructive pulmonary disease; CCI: Charlson Comorbidity Index; CI: confidence interval.